Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Holzmeister

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Lancet (London, England)|August 23, 2011
Implantable cardioverter defibrillators and cardiac resynchronisation therapyJohannes Holzmeister, Christophe Leclercq
Postgraduate Medicine|April 9, 2011
Recent advances in cardiac resynchronization therapyJan Steffel, Johannes Holzmeister, William T Abraham
Current Heart Failure Reports|March 7, 2009
Cardiac resynchronization therapy in patients with a narrow QRSJohannes Holzmeister, David Hürlimann, Jan Steffel, et al.
Future Cardiology|August 18, 2015
Ularitide: a natriuretic peptide candidate for the treatment of acutely decompensated heart failureSitaramesh Emani, Markus Meyer, Denada Palm, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|August 9, 2008
Long-term predictors of mortality in ICD patients with non-ischaemic cardiac disease: impact of renal functionThomy Schefer, Thomas Wolber, Christian Binggeli, et al.
Heart Rhythm|January 3, 2007
Potential interference of small neodymium magnets with cardiac pacemakers and implantable cardioverter-defibrillatorsThomas Wolber, Salome Ryf, Christian Binggeli, et al.
International Heart Journal|June 10, 2009
Predictors of appropriate implantable cardioverter-defibrillator therapy during long-term follow-up of patients with coronary artery diseaseJohannes Blumer, Thomas Wolber, Jens Hellermann, et al.
The American Journal of Cardiology|February 27, 2010
PQ interval in patients with Fabry diseaseMehdi Namdar, Christoph Kampmann, Jan Steffel, et al.
Danish Medical Journal|December 1, 2021
Ularitide as treatment of refractory ascites in cirrhosis- a study protocol for a randomised trialRasmus Hvidbjerg Gantzel, Markus Meyer, Stefan Mazgareanu, et al.
Heart (British Cardiac Society)|January 29, 2011
Electrocardiographic changes in early recognition of Fabry diseaseMehdi Namdar, Jan Steffel, Mile Vidovic, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Lancet (London, England)|August 23, 2011
Implantable cardioverter defibrillators and cardiac resynchronisation therapyJohannes Holzmeister, Christophe Leclercq
Postgraduate Medicine|April 9, 2011
Recent advances in cardiac resynchronization therapyJan Steffel, Johannes Holzmeister, William T Abraham
Current Heart Failure Reports|March 7, 2009
Cardiac resynchronization therapy in patients with a narrow QRSJohannes Holzmeister, David Hürlimann, Jan Steffel, et al.
Future Cardiology|August 18, 2015
Ularitide: a natriuretic peptide candidate for the treatment of acutely decompensated heart failureSitaramesh Emani, Markus Meyer, Denada Palm, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|August 9, 2008
Long-term predictors of mortality in ICD patients with non-ischaemic cardiac disease: impact of renal functionThomy Schefer, Thomas Wolber, Christian Binggeli, et al.
Heart Rhythm|January 3, 2007
Potential interference of small neodymium magnets with cardiac pacemakers and implantable cardioverter-defibrillatorsThomas Wolber, Salome Ryf, Christian Binggeli, et al.
International Heart Journal|June 10, 2009
Predictors of appropriate implantable cardioverter-defibrillator therapy during long-term follow-up of patients with coronary artery diseaseJohannes Blumer, Thomas Wolber, Jens Hellermann, et al.
The American Journal of Cardiology|February 27, 2010
PQ interval in patients with Fabry diseaseMehdi Namdar, Christoph Kampmann, Jan Steffel, et al.
Danish Medical Journal|December 1, 2021
Ularitide as treatment of refractory ascites in cirrhosis- a study protocol for a randomised trialRasmus Hvidbjerg Gantzel, Markus Meyer, Stefan Mazgareanu, et al.
Heart (British Cardiac Society)|January 29, 2011
Electrocardiographic changes in early recognition of Fabry diseaseMehdi Namdar, Jan Steffel, Mile Vidovic, et al.
Pageof 4